NLRP3 and cancer: Considering that immunotherapy has demonstrated impressive results, yet in a small proportion of cancer patients, we sought to investigate whether pharmacologic inhibition of NLRP3 inflammasome in combination with ICI immunotherapy may demonstrate a synergistic therapeutic effect in tumor-bearing animals.